Fast Locator 2011-2012: UPM Pharmaceuticals, Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: UPM Pharmaceuticals, Inc.



UPM Pharmaceuticals® is a Baltimore-based, independent provider of contract drug development, cGMP manufacturing and analytical testing services. We specialize in oral routes of administration with a focus on solid dosage forms. With our commitment to efficiency, timeliness and flexibility, we deliver industry-savvy, customer-focused services. Our scientists have extensive experience with product development challenges such as low dose content uniformity, high dose compressibility and controlled drug release rates. UPM has be helping clients successfully navigate the drug development continuum for the past two decades. Our extensive equipment train, experienced professional staff and our commitment to quality translates into success for each and every project.


Regions where services are provided:

Asia, North America, Europe, Latin America, Japan, & Middle East


Outsourcing serivces provided:

Development and Phase I/IICTM

  • Drug delivery
  • Solid dose, semisolids, and liquids development
  • Process development-small molecule

Commercial Manufacturing

  • Ingredient processing
  • Semisolids and liquids
  • Solid dosage forms
  • Specialty dosage forms

Analytical Services

  • Chemistry and stability
  • Particle characterization

Packaging and Logistics

  • Clinical labels
  • Clinical packaging and distribution

Website:

www.upm-inc.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
20%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
12%
Regulatory compliance
40%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here